The medical device firm cites a Category I CPT code transition easing prior authorization hurdles for its 2026 outlook.
CVRx set a 2026 revenue target of $63M to $67M, up from earlier expectations, after Q1 2026 results beat guidance. The company reported 22% U.S. growth in the quarter, driven by operational execution in 2025.
Management attributed the improved outlook to the transition of its therapy to a Category I CPT code, which simplifies prior authorization processes. The shift is expected to accelerate adoption and reduce administrative barriers for providers.
No immediate market reaction was disclosed in the earnings call summary.